Trade Veracyte Inc - VCYT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 41.02 |
| Open | 41.09 |
| 1-Year Change | 54.71% |
| Day's Range | 40.52 - 41.32 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 40.52 | -0.55 | -1.34% | 41.07 | 41.55 | 40.37 |
| Jan 16, 2025 | 41.02 | -0.51 | -1.23% | 41.53 | 41.84 | 40.19 |
| Jan 15, 2025 | 41.64 | -0.51 | -1.21% | 42.15 | 43.05 | 41.40 |
| Jan 14, 2025 | 41.01 | -1.69 | -3.96% | 42.70 | 43.33 | 40.18 |
| Jan 13, 2025 | 42.70 | 1.17 | 2.82% | 41.53 | 42.95 | 41.43 |
| Jan 10, 2025 | 41.52 | -0.75 | -1.77% | 42.27 | 42.33 | 40.39 |
| Jan 8, 2025 | 43.70 | 1.75 | 4.17% | 41.95 | 43.79 | 41.51 |
| Jan 7, 2025 | 42.41 | -0.96 | -2.21% | 43.37 | 44.27 | 42.01 |
| Jan 6, 2025 | 43.33 | 1.37 | 3.27% | 41.96 | 44.45 | 41.91 |
| Jan 3, 2025 | 41.80 | 1.41 | 3.49% | 40.39 | 41.87 | 40.27 |
| Jan 2, 2025 | 40.35 | 0.79 | 2.00% | 39.56 | 40.80 | 39.27 |
| Dec 31, 2024 | 39.52 | -0.43 | -1.08% | 39.95 | 40.44 | 39.35 |
| Dec 30, 2024 | 39.95 | 0.48 | 1.22% | 39.47 | 40.38 | 38.84 |
| Dec 27, 2024 | 40.07 | 0.11 | 0.28% | 39.96 | 40.73 | 39.66 |
| Dec 26, 2024 | 40.93 | 0.48 | 1.19% | 40.45 | 41.45 | 40.45 |
| Dec 24, 2024 | 41.05 | 0.09 | 0.22% | 40.96 | 41.20 | 40.17 |
| Dec 23, 2024 | 40.91 | 0.40 | 0.99% | 40.51 | 40.97 | 40.00 |
| Dec 20, 2024 | 40.83 | 2.36 | 6.13% | 38.47 | 41.30 | 38.36 |
| Dec 19, 2024 | 39.01 | -0.71 | -1.79% | 39.72 | 39.77 | 38.63 |
| Dec 18, 2024 | 39.35 | -2.72 | -6.47% | 42.07 | 42.50 | 38.97 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Veracyte Inc Company profile
About Veracyte Inc
Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Veracyte Inc revenues increased 87% to $219.5M. Net loss increased from $34.9M to $75.6M. Revenues reflect United States segment increase of 83% to $201M, International segment increase from $7.9M to $18.5M. Higher net loss reflects Selling and marketing - Balancing value increase of 54% to $75.4M (expense), General & Administrative Expenses increase of 47% to $42.2M (expense).
Equity composition
Common Stock, $0.001 Par, 10/13, 125M auth., 20,989,890 issd., Insiders Own 76.17%
| Industry: | Bio Diagnostics & Testing |
6000 Shoreline Court, Suite 300
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com